Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis

for the NIH Rare Lung Disease Consortium

Research output: Contribution to journalArticle

Abstract

Introduction: The Multicenter International Lymphangioleiomyomatosis (LAM) Efficacy of Sirolimus (MILES) trial revealed that sirolimus stabilised lung function in patients with moderately severe LAM. The purpose of this study was to further examine the MILES cohort for the effects of racial, demographic, clinical and physiological patient characteristics on disease progression and treatment response in LAM. Methods: MILES subjects were stratified on the basis of menopausal status (pre-menopausal/post-menopausal), race (Asian/Caucasian), bronchodilator responsiveness (present/absent), initial forced expiratory volume in 1 s (FEV1; 51–70% versus 50% predicted) and tuberous sclerosis complex (TSC) association (yes/ no). A linear mixed effects model was used to compare slope differences, and nonparametric tests were used to compare medians and proportions between treatment groups in each stratum. Results: In the MILES placebo group, pre-menopausal patients declined 5-fold faster than post-menopausal patients (mean±SE FEV1 slope −17±3 versus −3±3 mL·month −1 ; p=0.003). Upon treatment with sirolimus, both the pre-menopausal (−17±3 versus −1±2 mL·month −1 ; p<0.0001) and post-menopausal patients (−3±3 versus 6±3 mL·month −1 ; p=0.04) exhibited a beneficial response in mean±SE FEV1 slope compared with the placebo group. Race, LAM subtype, bronchodilator responsiveness or baseline FEV1 did not impact the rate of disease progression in the placebo group or treatment response in the sirolimus group. Menopausal status and race had differential effects on the adverse event profile of sirolimus. Baseline serum vascular endothelial growth factor (VEGF)-D >600 pg·mL −1 identified subgroups of patients who were more likely to decline on placebo and respond to treatment with sirolimus. Conclusions: In LAM patients, treatment with sirolimus is beneficial regardless of menopausal status, race, bronchodilator responsiveness, baseline FEV1 or TSC association. Serum VEGF-D and menopausal status can help inform therapeutic decisions.

Original languageEnglish (US)
Article number1802066
JournalEuropean Respiratory Journal
Volume53
Issue number4
DOIs
StatePublished - Apr 1 2019

Fingerprint

Lymphangioleiomyomatosis
Sirolimus
Disease Progression
Cohort Studies
Bronchodilator Agents
Vascular Endothelial Growth Factor D
Placebos
Tuberous Sclerosis
Therapeutics
Cohort Effect
Forced Expiratory Volume
Serum
Demography
Lung

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis. / for the NIH Rare Lung Disease Consortium.

In: European Respiratory Journal, Vol. 53, No. 4, 1802066, 01.04.2019.

Research output: Contribution to journalArticle

@article{17b31dbde50942e09d1978e5f2d96951,
title = "Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis",
abstract = "Introduction: The Multicenter International Lymphangioleiomyomatosis (LAM) Efficacy of Sirolimus (MILES) trial revealed that sirolimus stabilised lung function in patients with moderately severe LAM. The purpose of this study was to further examine the MILES cohort for the effects of racial, demographic, clinical and physiological patient characteristics on disease progression and treatment response in LAM. Methods: MILES subjects were stratified on the basis of menopausal status (pre-menopausal/post-menopausal), race (Asian/Caucasian), bronchodilator responsiveness (present/absent), initial forced expiratory volume in 1 s (FEV1; 51–70{\%} versus 50{\%} predicted) and tuberous sclerosis complex (TSC) association (yes/ no). A linear mixed effects model was used to compare slope differences, and nonparametric tests were used to compare medians and proportions between treatment groups in each stratum. Results: In the MILES placebo group, pre-menopausal patients declined 5-fold faster than post-menopausal patients (mean±SE FEV1 slope −17±3 versus −3±3 mL·month −1 ; p=0.003). Upon treatment with sirolimus, both the pre-menopausal (−17±3 versus −1±2 mL·month −1 ; p<0.0001) and post-menopausal patients (−3±3 versus 6±3 mL·month −1 ; p=0.04) exhibited a beneficial response in mean±SE FEV1 slope compared with the placebo group. Race, LAM subtype, bronchodilator responsiveness or baseline FEV1 did not impact the rate of disease progression in the placebo group or treatment response in the sirolimus group. Menopausal status and race had differential effects on the adverse event profile of sirolimus. Baseline serum vascular endothelial growth factor (VEGF)-D >600 pg·mL −1 identified subgroups of patients who were more likely to decline on placebo and respond to treatment with sirolimus. Conclusions: In LAM patients, treatment with sirolimus is beneficial regardless of menopausal status, race, bronchodilator responsiveness, baseline FEV1 or TSC association. Serum VEGF-D and menopausal status can help inform therapeutic decisions.",
author = "{for the NIH Rare Lung Disease Consortium} and Nishant Gupta and Lee, {Hye Seung} and Young, {Lisa R.} and Charlie Strange and Joel Moss and Singer, {Lianne G.} and Koh Nakata and Alan Barker and Chapman, {Jeffrey T.} and Brantly, {Mark L.} and Stocks, {James M.} and Brown, {Kevin K.} and Lynch, {Joseph P.} and Goldberg, {Hilary J.} and Downey, {Gregory P.} and Taveira-DaSilva, {Angelo M.} and Krischer, {Jeffrey P.} and Kenneth Setchell and Trapnell, {Bruce C.} and Yoshikazu Inoue and McCormack, {Francis X.}",
year = "2019",
month = "4",
day = "1",
doi = "10.1183/13993003.02066-2018",
language = "English (US)",
volume = "53",
journal = "European Respiratory Journal, Supplement",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "4",

}

TY - JOUR

T1 - Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis

AU - for the NIH Rare Lung Disease Consortium

AU - Gupta, Nishant

AU - Lee, Hye Seung

AU - Young, Lisa R.

AU - Strange, Charlie

AU - Moss, Joel

AU - Singer, Lianne G.

AU - Nakata, Koh

AU - Barker, Alan

AU - Chapman, Jeffrey T.

AU - Brantly, Mark L.

AU - Stocks, James M.

AU - Brown, Kevin K.

AU - Lynch, Joseph P.

AU - Goldberg, Hilary J.

AU - Downey, Gregory P.

AU - Taveira-DaSilva, Angelo M.

AU - Krischer, Jeffrey P.

AU - Setchell, Kenneth

AU - Trapnell, Bruce C.

AU - Inoue, Yoshikazu

AU - McCormack, Francis X.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Introduction: The Multicenter International Lymphangioleiomyomatosis (LAM) Efficacy of Sirolimus (MILES) trial revealed that sirolimus stabilised lung function in patients with moderately severe LAM. The purpose of this study was to further examine the MILES cohort for the effects of racial, demographic, clinical and physiological patient characteristics on disease progression and treatment response in LAM. Methods: MILES subjects were stratified on the basis of menopausal status (pre-menopausal/post-menopausal), race (Asian/Caucasian), bronchodilator responsiveness (present/absent), initial forced expiratory volume in 1 s (FEV1; 51–70% versus 50% predicted) and tuberous sclerosis complex (TSC) association (yes/ no). A linear mixed effects model was used to compare slope differences, and nonparametric tests were used to compare medians and proportions between treatment groups in each stratum. Results: In the MILES placebo group, pre-menopausal patients declined 5-fold faster than post-menopausal patients (mean±SE FEV1 slope −17±3 versus −3±3 mL·month −1 ; p=0.003). Upon treatment with sirolimus, both the pre-menopausal (−17±3 versus −1±2 mL·month −1 ; p<0.0001) and post-menopausal patients (−3±3 versus 6±3 mL·month −1 ; p=0.04) exhibited a beneficial response in mean±SE FEV1 slope compared with the placebo group. Race, LAM subtype, bronchodilator responsiveness or baseline FEV1 did not impact the rate of disease progression in the placebo group or treatment response in the sirolimus group. Menopausal status and race had differential effects on the adverse event profile of sirolimus. Baseline serum vascular endothelial growth factor (VEGF)-D >600 pg·mL −1 identified subgroups of patients who were more likely to decline on placebo and respond to treatment with sirolimus. Conclusions: In LAM patients, treatment with sirolimus is beneficial regardless of menopausal status, race, bronchodilator responsiveness, baseline FEV1 or TSC association. Serum VEGF-D and menopausal status can help inform therapeutic decisions.

AB - Introduction: The Multicenter International Lymphangioleiomyomatosis (LAM) Efficacy of Sirolimus (MILES) trial revealed that sirolimus stabilised lung function in patients with moderately severe LAM. The purpose of this study was to further examine the MILES cohort for the effects of racial, demographic, clinical and physiological patient characteristics on disease progression and treatment response in LAM. Methods: MILES subjects were stratified on the basis of menopausal status (pre-menopausal/post-menopausal), race (Asian/Caucasian), bronchodilator responsiveness (present/absent), initial forced expiratory volume in 1 s (FEV1; 51–70% versus 50% predicted) and tuberous sclerosis complex (TSC) association (yes/ no). A linear mixed effects model was used to compare slope differences, and nonparametric tests were used to compare medians and proportions between treatment groups in each stratum. Results: In the MILES placebo group, pre-menopausal patients declined 5-fold faster than post-menopausal patients (mean±SE FEV1 slope −17±3 versus −3±3 mL·month −1 ; p=0.003). Upon treatment with sirolimus, both the pre-menopausal (−17±3 versus −1±2 mL·month −1 ; p<0.0001) and post-menopausal patients (−3±3 versus 6±3 mL·month −1 ; p=0.04) exhibited a beneficial response in mean±SE FEV1 slope compared with the placebo group. Race, LAM subtype, bronchodilator responsiveness or baseline FEV1 did not impact the rate of disease progression in the placebo group or treatment response in the sirolimus group. Menopausal status and race had differential effects on the adverse event profile of sirolimus. Baseline serum vascular endothelial growth factor (VEGF)-D >600 pg·mL −1 identified subgroups of patients who were more likely to decline on placebo and respond to treatment with sirolimus. Conclusions: In LAM patients, treatment with sirolimus is beneficial regardless of menopausal status, race, bronchodilator responsiveness, baseline FEV1 or TSC association. Serum VEGF-D and menopausal status can help inform therapeutic decisions.

UR - http://www.scopus.com/inward/record.url?scp=85064012371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064012371&partnerID=8YFLogxK

U2 - 10.1183/13993003.02066-2018

DO - 10.1183/13993003.02066-2018

M3 - Article

VL - 53

JO - European Respiratory Journal, Supplement

JF - European Respiratory Journal, Supplement

SN - 0903-1936

IS - 4

M1 - 1802066

ER -